Pharmaceutical manufacturers are padding their wallets while rural families and retirees are squeezed by a system designed to benefit shareholders, not patients,” writes Tonja Hanson in an op-ed.

Generic drugmakers and hospital pharmacists warn that added financial pressure from tariffs could strain the nation's generic drug supplies.

The National Board of Revenue (NBR) has exempted advance tax on the import of raw materials used to manufacture cancer drugs, ...

The Trump administration is experiencing some cognitive dissonance: The new president’s Justice Department is going to bat ...

"Competition plays a crucial role in determining drug prices. When a new cancer drug is introduced by a single manufacturer, its cost is typically high due to research and development costs.

A very bullish analyst move was the news generally responsible for Summit Therapeutics' (NASDAQ: SMMT) healthy mid-week stock ...

AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that support a wide moat. The strong replenishment of new drugs sets ...

Bristol Myers Squibb said it will acquire its struggling CAR-T partner 2Seventy Bio for $286 million, or $102 million net of ...

Under the deal, Sun Pharma will buy the outstanding shares of the Massachusetts-based company for $4.10 each, representing a premium of approximately 66% to Checkpoint’s closing share price last ...

Belgium first called for a law to tackle drug shortages in May 2023. Belgium was the architect of a European plan to tackle ...

The second cycle of negotiations will take place under President Donald Trump's administration. The U.S. government has said ...

In our oncology focus month, Ryan McGuire takes a look at the impact of clinical development on cancer drug prices and the factors involved in the current improved success rate for cancer treatments.